Form 4: Eli Lilly CEO David Ricks Reports Stock Transactions

Eli Lilly CEO David Ricks acquired shares and restricted stock units, while also reporting changes in his indirect holdings.

Summary

• David Ricks, CEO of Eli Lilly, reported acquiring 38,392 shares of common stock at a price of $737.26 on February 12, 2024.
• He also acquired 26,561 restricted stock units, each representing a contingent right to receive one share of Eli Lilly common stock, exercisable on February 1, 2025.
• The report details changes in his indirect holdings, including 7,223 shares held in a 401(k), 68,656 shares held through a SLAT, and 63,758 shares held through a 2022 GRAT.
• The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing and does not indicate any positive or negative sentiment. It is a neutral reporting of transactions.

Management Comments

• The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Industry Context

This is a routine filing for a company executive and is not unusual in the pharmaceutical industry.

Comparison to Industry Standards

• Executive stock transactions are common across all publicly traded companies, including pharmaceutical companies like Pfizer (PFE) and Merck (MRK).
• The reporting of these transactions is a standard practice to ensure transparency and prevent insider trading.
• The size of the transaction is not unusual for a CEO of a large cap company.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on stakeholders as it is a routine filing.

Key Dates

Keywords

Eli Lilly, LLY, David Ricks, stock acquisition, restricted stock units, insider trading, SEC Form 4, beneficial ownership